Fifteen years' single-center experience with the ATS bileaflet valve.

BACKGROUND AND AIM OF THE STUDY Since its introduction in May 1992, the bileaflet ATS Open Pivot valve has been implanted routinely at the authors' institution. The study aim was to analyze, retrospectively, the 15-year clinical results of these implanted ATS valves. METHODS Between May 1992 and December 2005, a total of 1,160 ATS valves (749 aortic, 381 mitral, 21 tricuspid, nine pulmonary) was implanted in 1,047 consecutive patients (655 males, 392 females; mean age 62.1 +/- 12.4 years). Preoperatively, 75% of the patients were in NYHA class III or higher (mean 3.1). The most frequent comorbidities included atrial fibrillation (n = 381), coronary disease (n = 288) and diabetes (n = 172). RESULTS The mean follow up was 78 months (range: 24-183 months); the total follow up was 6,887 patient-years (pt-yr) and was 99.8% complete. In-hospital mortality was 4% (n = 43; three valve-related). Survival (Kaplan-Meier) at five and 10 years was significantly better for aortic than for mitral valve patients (84% and 65% versus 75% and 41%, respectively) (Mantel-Cox, p < 0.001). A log rank analysis detected no statistical difference in the incidence of thromboembolism (p = 0.182) or bleeding (p = 0.375) between both groups. The overall linearized incidences were: thromboembolism 1.08%/pt-yr; bleeding 0.91%/pt-yr; endocarditis 0.22%/pt-yr; paravalvular leakage 0.33%/pt-yr; and valve thrombosis 0.21%/pt-yr. Multivariate analysis (Cox regression) indicated age > 70 years (p < 0.0001), NYHA class > or = III (p < 0.0001), non-sinus rhythm (p = 0.001), concomitant CABG (p = 0.008) and higher INR values (p = 0.013) to be significant risk factors for death. CONCLUSION This 15-year experience with the ATS bileaflet prosthesis showed excellent clinical outcomes for patients, with no structural failure and an acceptable incidence of adverse events.

[1]  G. Tenderich,et al.  Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II. , 2007, European heart journal.

[2]  J. Monro,et al.  Mid-term results with 1,503 CarboMedics mechanical valve implants. , 2000, The Journal of heart valve disease.

[3]  J. Mayer,et al.  Guidelines for reporting mortality and morbidity after cardiac valve interventions. , 2008, The Annals of thoracic surgery.

[4]  C. E. Rasmussen,et al.  Twelve years' clinical experience with the CarboMedics prosthetic heart valve. , 2001, Journal of Heart Valve Disease.

[5]  D. Massel,et al.  Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. , 2001, Journal of the American College of Cardiology.

[6]  G. Angelini,et al.  Prospective randomized comparison of CarboMedics and St. Jude Medical bileaflet mechanical heart valve prostheses: ten-year follow-up. , 2007, The Journal of thoracic and cardiovascular surgery.

[7]  T. Ebels,et al.  RATES OF THROMBOEMBOLISM WITH THREE DIFFERENT MECHANICAL HEART VALVE PROSTHESES: RANDOMISED STUDY , 1989, The Lancet.

[8]  Robert W Emery,et al.  The initial experience with the ATS Medical mechanical cardiac valve prosthesis. , 2003, The Annals of thoracic surgery.

[9]  M. Lengyel Diagnosis and treatment of left-sided prosthetic valve thrombosis , 2008, Expert review of cardiovascular therapy.

[10]  L. Grize,et al.  Single-center outcome analysis of 1,161 patients with St. Jude medical and ATS open pivot mechanical heart valves. , 2007, The Journal of heart valve disease.

[11]  Y. Taeymans,et al.  Lower-intensity anticoagulation for mechanical heart valves: a new concept with the ATS bileaflet aortic valve. , 2003, The Journal of heart valve disease.

[12]  G. Albers Warfarin prevails for stroke prevention in atrial fibrillation—even in octogenarians , 2007, The Lancet Neurology.

[13]  R. Petersen,et al.  Anticoagulant related complications in elderly patients with St. Jude mechanical valve prostheses. , 1996, The Journal of heart valve disease.

[14]  S Westaby,et al.  Valve replacement with the ATS open pivot bileaflet prosthesis. , 1996, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[15]  R. Emery,et al.  The St. Jude Medical cardiac valve prosthesis: a 25-year experience with single valve replacement. , 2005, The Annals of thoracic surgery.

[16]  L. Missault,et al.  Clinical Experience with the First 100 ATS Heart Valve Implants , 1996, Cardiovascular surgery.

[17]  R. Emery,et al.  Anticoagulation for mechanical heart valves: a role for patient based therapy , 2008, Journal of Thrombosis and Thrombolysis.

[18]  O. Lund,et al.  Standard aortic St. Jude valve at 18 years: performance profile and determinants of outcome. , 2000, The Annals of thoracic surgery.

[19]  M. Carrier,et al.  Prosthetic valve thrombosis: twenty-year experience at the Montreal Heart Institute. , 2004, The Journal of thoracic and cardiovascular surgery.